| Followers | 312 |
| Posts | 10714 |
| Boards Moderated | 16 |
| Alias Born | 02/24/2010 |
Saturday, October 09, 2021 5:37:40 AM
I don't know what happens here, we are at liquidation value right now. Incoming events, coming tuesday just a simple convention, and in November a full data readout.
Maybe M&A will happen, maybe not, we just don't know. Just stick to the potential of the science, that's it guys.
There is not a big risk of dilution, certainly not after the result of the vote.
It's clear that their initial target was to have 400m shares issuable, so they could issue the 320m shares on the shelf for the maximum of 350 million dollar they were cleared to. Let's say $1.10
Next play was the 240m shares issuable, so they had 160m shares to offer for the max of 350m dollar. Let's say $2.20
Now they have only 40m shares left to offer, for the max of 350m dollar. Let's say $9 bucks.
Conclusion, I don't know whether M&A will happen, maybe the ''Change of Control'' thing has to do with something else. Fact is, the potential here is HUGE, and the risk is LOW.
Low Risk, High Reward, as Warren likes 'em.
$HEPA
Maybe M&A will happen, maybe not, we just don't know. Just stick to the potential of the science, that's it guys.
There is not a big risk of dilution, certainly not after the result of the vote.
It's clear that their initial target was to have 400m shares issuable, so they could issue the 320m shares on the shelf for the maximum of 350 million dollar they were cleared to. Let's say $1.10
Next play was the 240m shares issuable, so they had 160m shares to offer for the max of 350m dollar. Let's say $2.20
Now they have only 40m shares left to offer, for the max of 350m dollar. Let's say $9 bucks.
Conclusion, I don't know whether M&A will happen, maybe the ''Change of Control'' thing has to do with something else. Fact is, the potential here is HUGE, and the risk is LOW.
Low Risk, High Reward, as Warren likes 'em.
$HEPA
Recent HEPA News
- Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma • GlobeNewswire Inc. • 03/03/2026 12:35:00 PM
- Hepion Pharmaceuticals Successfully Completes Application to the OTCQB • GlobeNewswire Inc. • 06/25/2025 12:30:00 PM
- Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer • GlobeNewswire Inc. • 06/16/2025 12:30:00 PM

